Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Mydecine Innovations Group Inc (MYCO.NE)

Mydecine Innovations Group Inc (MYCO.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Globe Newswire - Tue Jul 19, 2022

Company aims to increase health equity by developing more accessible treatment modalities better suited for existing healthcare infrastructure...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation Globe Newswire - Fri Jun 17, 2022

DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)
Mydecine Provides Company Update; Welcomes New Board Member Globe Newswire - Thu Jun 9, 2022

DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)
Mydecine Announces First Quarter 2022 Financial Results and Highlights Globe Newswire - Mon May 16, 2022

DENVER, May 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)
American Billionaire Entrepreneurs Bet Millions on Psychedelics FinancialNewsMedia - Tue May 10, 2022

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman...

CYBN.NE : 13.8000 (+3.60%)
MYCO.NE : 0.1400 (+3.70%)
PYPL : 87.13 (+0.40%)
TSLA : 421.06 (-3.46%)
CYBN : 9.61 (+3.11%)
MYCOF : 0.0040 (-31.03%)
NUMI.TO : 0.0450 (+12.50%)
NUMIF : 0.0300 (+0.33%)
ATAI : 1.1900 (unch)
ENVB : 0.3250 (-1.04%)
Why Psychedelics Could Soon Replace Antidepressants FinancialNewsMedia - Wed Apr 13, 2022

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...

CYBN.NE : 13.8000 (+3.60%)
MMED.NE : 14.9000 (+9.48%)
MYCO.NE : 0.1400 (+3.70%)
SEEL : 0.3900 (-27.79%)
MNMD : 7.16 (+2.07%)
CMPS : 3.97 (+1.28%)
MYCOF : 0.0040 (-31.03%)
CYBN : 9.61 (+3.11%)
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update Globe Newswire - Thu Mar 31, 2022

MYCO-001 Smoking Cessation Clinical Trial Moves Forward Following Conditional IRB Approval Company Advances IP Portfolio With New Patent Applications...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
Demand for Toad Venom Rises Along With the Booming Psychedelics Market FinancialNewsMedia - Wed Mar 30, 2022

FN Media Group Presents Microsmallcap.com Market Commentary   New York, NY – March 30, 2022 –  Depression and anxiety affect millions around the world and the venom of a toad is the latest  psychedelic...

MMED.NE : 14.9000 (+9.48%)
MYCO.NE : 0.1400 (+3.70%)
NUMI.TO : 0.0450 (+12.50%)
NUMIF : 0.0300 (+0.33%)
SEEL : 0.3900 (-27.79%)
MNMD : 7.16 (+2.07%)
MYCOF : 0.0040 (-31.03%)
CMPS : 3.97 (+1.28%)
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study Globe Newswire - Thu Mar 24, 2022

Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)
Mydecine To Attend March Investor Conferences Globe Newswire - Thu Mar 3, 2022

Learn more about Mydecine’s clinical trials and drug development strategy by scheduling a meeting with management...

MYCO.NE : 0.1400 (+3.70%)
OTC.VN : 0.330 (+3.13%)
MYCOF : 0.0040 (-31.03%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - 1 hour ago
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot